|
The Effect of Hyoscine Butylbromide for Shortening the Active Phase of the First Stage of Labor: A randomized, double-blind, placebo-controlled trial |
|---|---|
| รหัสดีโอไอ | |
| Creator | Jongruk Kamkong |
| Title | The Effect of Hyoscine Butylbromide for Shortening the Active Phase of the First Stage of Labor: A randomized, double-blind, placebo-controlled trial |
| Contributor | Manasicha Pongsamakthai, Maleechat Sripipatanakul, Thumwadee Tangsiriwatthana |
| Publisher | PIMDEE Co., Ltd. |
| Publication Year | 2567 |
| Journal Title | Thai Journal of Obstetrics and Gynaecology |
| Journal Vol. | 32 |
| Journal No. | 3 |
| Page no. | 245-253 |
| Keyword | hyoscine butylbromide, first stage of labor, duration of labor |
| URL Website | https://tci-thaijo.org/index.php/tjog/index |
| Website title | www.tci-thaijo.org |
| ISSN | 2673-0871 |
| Abstract | Objectives: To study the efficacy and safety of hyoscine butylbromide for shortening the active phase of the first stage of labor.Materials and Methods: After receiving informed consent, singleton pregnant women who planned vaginal delivery at Khon Kaen Hospital between July 2022 and April 2023 were randomly allocated into two groups: the control group (n = 61) received 1 mL (20 mg) of intravascular hyoscine butylbromide, while the control group (n = 61) received 1 mL of intravascular normal saline at 5-6 cm cervical dilatation. The duration of the active phase of the first stage of labor and adverse events were analyzed.Results: Baseline characteristics were not statistically different between groups. Hyoscine butylbromide significantly shortened the active phase of the first stage of labor compared to the control group (88.5 ? 66.7 min vs 188.5 ? 101.9 min, respectively, mean difference -100.02 min (95% confidence interval -130.72 to -69.31, p <0.001)). There were no significant maternal or neonatal adverse outcomes.Conclusion: Hyoscine butylbromide effectively shortened the active phase of the first stage of labor. |
